1 week Ago By ABMN Staff
Astria Therapeutics, Inc. ( NASDAQ:ATXS – Get Free Report ) has been given an average rating of “Buy” by the six analysts that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.
The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $25.60. ATXS has been the topic of a number of research reports.
Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.
HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, December 10th. Read Our Latest Stock Report on Astria Therapeutics Institutional Inflows and Outflows Astria Therapeutics Stock Performance Astria Therapeutics stock opened at $9.
52 on Thursday. Astria Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $16.
90. The firm’s fifty day moving average price is $10.65 and its 200-day moving average price is $10.
72. The stock has a market cap of $537.25 million, a P/E ratio of -4.
56 and a beta of 0.67. Astria Therapeutics Company Profile ( Get Free Report Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. Recommended Stories Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
